Special Feature Webinar: Hormone Therapy Unlocked: Case Studies in Diagnosing and Managing Hypoactive Sexual Desire Disorder and Menopausal Hormone Therapy

August 13, 2025

This interactive Special Feature Webinar uses real-world case studies to guide clinicians through the complexities of diagnosing and managing hypoactive sexual desire disorder and menopausal symptoms in women. This is a follow-on to the Women’s Health Clinical Communities Speaker Series session, “Hormone Therapy Unlocked: Overcoming Barriers to Better Care.”

Date: Wednesday, August 13, from 1:00 PM ET to 2:30 PM ET
Meeting: Join on Microsoft Teams
Credit: 1.50 CE/CME credits

Credit types available are TBD. Check back closer to the event for more details.

Learning Objectives

Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making.
Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use.
Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects.
Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making.
Assess suitability for MHT in women with chronic disease, using a thorough history and risk stratification based on current guidelines.
Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral).
Formulate an individualized menopausal hormone therapy (MHT) plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy.
Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline.

Course summary

Available credit:

1.50 Attendance
1.50 IPCE
In support of improving patient care, DHA, J-7, CEPO is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Course opens:

06/23/2025

Course expires:

08/27/2025

Event starts:

08/13/2025 - 1:00pm EDT

Event ends:

08/13/2025 - 2:30pm EDT

Add to calendar:

Presenting Faculty

Rebbecca Hertel, DO, MSCP
Family Physician, Certified Menopause Practitioner, and Founder of Osteopathic Midlife Health

Heather Quaile, DNP, WHNP-BC, AFN-C, CSC, I.F., FAANP
Scientific Committee Chair for the International Society for the Study of Women’s Sexual Health and Founder of the Sexual Health Optimization and Wellness Center

Air Force Lt. Col. Samantha Simpson, M.D.
Chief of the Reproductive Endocrinology and Infertility Division and Program Director for the SAUSHEC OB/GYN Residency Program, Brooke Army Medical Center

Retired Air Force Col. Christine Kress, DNP, APRN, WHNP-BC, NEA-BC, MSCP
Women’s Health Nurse Practitioner and Certified Menopause Practitioner, Heather Hirsch MD Collaborative

Aoife O’Sullivan, M.D., NCMP
Family Physician, Certified Menopause Practitioner, and Founder of Portland Menopause Doc

Disclosure: DHA J-7 staff, planners, faculty, and content reviewers for this educational activity have no financial or non-financial relationship(s) with ineligible companies to disclose.

Speaker(s)